Healios K.K (HLOSF PINK) stock market data APIs
$2.1981
0(0%)
as of May 4, 2026
Try our APIs with
free plan!
Healios K.K Financial Data Overview
Price chart is built with
Anychart
Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for the treatment of retinal pigmen epithelium and age-related macular degeneration and AKT-01/HLCN061, which is in pre-clinical trial for the treatment of Mesothelioma, Lung cancer, Hepatocellular carcinoma and Gastric cancer(solid tumors). It also develops somatic stem cell and induced pluripotent stem cell regenerative medicines. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Chiyoda, Japan.
Prev. Close
2.1981
Open
2.1981
High
2.1981
Low
2.1981
52 wk Range
1.9-4.45
Market Cap
297 M
Shares Outstanding
135 M
Revenue
104 M
EPS
0.1082
Beta
1.387
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Healios K.K data using free add-ons & libraries
Get Healios K.K Fundamental Data
Healios K.K Fundamental data includes:
- Net Revenue: 104 M
- EBITDA: -3 059 000 064
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-12-31
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Healios K.K News
New
Athersys and Healios K.K. Announce Advancement of Their MultiStem Commercial Partnership
Improvements to Collaboration Enhance Preparations for Commercial Activity in Japan CLEVELAND & TOKYO, August 05, 2021--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX) and HEALIOS K.K. (Healios) (TSE ...
Healios Successfully Establishes Proprietary Universal Donor Cell Research Line
TOKYO, June 5, 2020 /PRNewswire/ -- Healios K.K. (hereinafter "the Company"; TSE: 4593), Japan's leading clinical-stage biotechnology company, has been creating Universal Donor Cells (UDCs), which are...
Get Healios K.K fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
